Markets:

Overview

News

Currencies

International

Treasuries

Can-Fite Biopharma Ltd Sponsored ADR (Israel) (NY:CANF)

0.3390 -0.0030 (-0.88%)

Official Closing Price Updated: 4:10 PM EST, Dec 4, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Can-Fite Biopharma Ltd Sponsored ADR (Israel)

< Previous 1 2 3 4 5 6 7 Next >

Hope on the Horizon for Liver Cancer Patients as This Company's Namodenoson Drug Starts Pivotal Phase III Global Trial ↗

October 08, 2021

Photo by National Cancer Institute on Unsplash Liver cancer is a growing global health concern. Apart from the financial burden it places on patients and economies, the American...

Via Benzinga

Can-Fite to Present at H.C. Wainwright 5th Annual NASH Investor Conference on October 12, 2021

October 05, 2021

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite CEO to Join Benzinga Medical Cannabis Panel and Deliver Company Presentation at Healthcare Small Cap Conference on September 29, 2021

September 22, 2021

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite to Participate in Three Upcoming Pharma Partnering Conferences

September 17, 2021

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

September 09, 2021

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite Completes Patient Enrollment in Phase III Psoriasis Study

September 02, 2021

From Can-Fite BioPharma Ltd.

Via Business Wire

The Week In Cannabis: $1.25B+ In Financings And M&A, Tilray, KushCo, New York And More ↗

August 27, 2021

Below is a recap of the main news related to the cannabis industry and markets for the week of August 27, 2021.

Via Benzinga

Topics Cannabis

Can-Fite Reports Drop In H1 2021 Revenue, Net Loss Down By 38% YoY ↗

August 26, 2021

Biotechnology company Can-Fite BioPharma Ltd. (NYSE: CANF) (TASE: CFBI) announced its financial results Thursday for the quarter ended June 30, 2021. The Israel-based company...

Via Benzinga

Can-Fite Reports Second Quarter 2021 Financial Results & Provides Clinical Update

August 26, 2021

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite Announces $10.0 Million Registered Direct Offering

August 12, 2021

From Can-Fite BioPharma Ltd.

Via Business Wire

Yossi Borenstein, CEO and Founder of Shizim Group, has been Elected to the Can-Fite Board

August 05, 2021

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite Gears Up to Initiate Pivotal Phase III Liver Cancer Study

July 08, 2021

From Can-Fite BioPharma Ltd.

Via Business Wire

The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test ↗

July 08, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 7) Ambrx Biopharma Inc. (NYSE:...

Via Benzinga

Topics Product Recall

Can-Fite Stock Gains On Piclidenoson Development Pact For Pets ↗

June 28, 2021

Can-Fite BioPharma Ltd (NYSE: CANF) has signed a development and commercialization agreement with France-based veterinary biotech company, Vetbiolix, to...

Via Benzinga

Can-Fite Enters Projected $3 Billion Veterinary Osteoarthritis Market: Signs Agreement with Vetbiolix for Development of Piclidenoson for Pets

June 28, 2021

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite Receives Notice of Patent Allowance in China for NASH Treatment

June 16, 2021

From Can-Fite BioPharma Ltd.

Via Business Wire

CAN-FITE AHEAD OF SCHEDULE IN ITS FIGHT TO TREAT NASH AND LESSEN THE NEED FOR LIVER TRANSPLANTS ↗

June 03, 2021

Nonalcoholic steatohepatitis (NASH) is the leading cause of disease leading to liver transplants among women and the second-leading cause for liver transplants overall. In...

Via Benzinga

Can-Fite To Initiate Phase IIb NASH Study with its Drug Candidate Namodenoson

June 02, 2021

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite to Present at BIO Digital International Convention & Conduct One-on-One Meetings with Potential Partners on June 10-18, 2021

June 02, 2021

From Can-Fite BioPharma Ltd.

Via Business Wire

CAN-FITE BIOPHARMA ANNOUNCES ADVANCEMENT OF CLINICAL STUDIES AND NEW EUROPEAN LICENSING AGREEMENTS ↗

May 27, 2021

by Mark Gilman Can-Fite BioPharma Ltd. (NYSE: CANF) (TASE: CFBI), an Israeli-based biotechnology company advancing a pipeline of proprietary small-molecule drugs that address...

Via Benzinga

The Daily Biotech Pulse: Vir-GlaxoSmithKline COVID-19 Antibody Treatment Approved, Zosano Spikes On Long-Term Migraine Drug Data, Decision Day For Eton, 2 IPOs ↗

May 27, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 26) I-Mab (NASDAQ: IMAB)...

Via Benzinga

Can-Fite Reports First Quarter 2021 Financial Results & Provides Clinical Update

May 27, 2021

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite BioPharma Interview to Air on Bloomberg Television U.S. on the RedChip Money Report®

May 27, 2021

From Can-Fite BioPharma Ltd.

Via Business Wire

CAN-FITE BIOPHARMA GAINS ANALYST "BUY" DISTINCTION AND SIGNS NEW DISTRIBUTION AGREEMENTS FOR ITS LEAD DRUG CANDIDATES ↗

May 12, 2021

Can-Fite BioPharma Ltd. (NYSE: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver...

Via Benzinga

Can-Fite to Present at Benzinga’s Global Small Cap Conference on May 13, 2021

May 06, 2021

From Can-Fite BioPharma Ltd.

Via Business Wire

The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx ↗

April 29, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 28) Axonics, Inc. (NASDAQ:...

Via Benzinga

Can-Fite’s Phase III Psoriasis Study Achieves 75% Enrollment; Top Line Results Expected Q4 2021

April 29, 2021

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite Expands Mid-Stage COVID-19 Study To Europe ↗

April 22, 2021

Can-Fite BioPharma Ltd (NYSE: CANF) has expanded its Phase 2 COVID-19 study of Piclidenoson to two European countries, Romania and Bulgaria. The randomized,...

Via Benzinga

Can-Fite Expands its Phase II COVID-19 Study to Europe

April 22, 2021

From Can-Fite BioPharma Ltd

Via Business Wire

Can-Fite Starts Preclinical Studies Required By FDA, EMA For Two Lead Drug Candidates Registration Filing ↗

April 20, 2021

Can-Fite BioPharma (NYSE: CANF) has initiated a series of preclinical studies required by regulators to support potential marketing registration filings for...

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.